BioCentury | Feb 24, 2014
Company News

Oxford BioMedica, Sanofi deal

...ocular disease indications in exchange for the return to Oxford of all worldwide rights to EncorStat...
...license to develop and commercialize four preclinical compounds to treat ocular diseases, including StarGen, UshStat, EncorStat...
...for the indication. Oxford BioMedica plans to begin a U.K. Phase I/IIa trial to evaluate EncorStat...
BioCentury | Jul 9, 2012
Company News

Oxford BioMedica, Sanofi deal

...2009). The 2009 deal also included options for licenses to LentiVector-based gene therapies, RetinoStat and EncorStat...
...and is in Phase I testing for wet age-related macular degeneration (AMD). Oxford BioMedica said EncorStat...
BioCentury | Feb 1, 2010
Company News

Oxford BioMedica, Clayton Foundation for Research deal

...payment and is eligible for royalties. Further terms were not disclosed. Oxford BioMedica's RetinoStat and EncorStat...
BioCentury | May 4, 2009
Company News

Oxford BioMedica, sanofi-aventis deal

...a corrected version of the myosin VIIA (MYO7A) (USH1B) for Usher syndrome type 1B; and EncorStat...
Items per page:
1 - 4 of 4